The University of Southampton
University of Southampton Institutional Repository

Anti-CD20 monoclonal antibodies: historical and future perspectives

Anti-CD20 monoclonal antibodies: historical and future perspectives
Anti-CD20 monoclonal antibodies: historical and future perspectives
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced. In this review, we discuss the history of anti-CD20 monoclonal antibodies, detail their likely mechanisms of action, and explore ways in which they might be enhanced and further exploited in the future. In particular, as we develop our understanding of the relative contribution of the diverse effector mechanisms for different antibodies, so we hope to clarify which reagent will be the most effective in each clinical situation.

cd20, monoclonal antibodies, lymphoma, immunotherapy
0390-6078
135-143
Lim, Sean H.
1afe5aa1-61a4-4a7b-927f-5e671f885196
Beers, Stephen A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Johnson, Peter W.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Lim, Sean H.
1afe5aa1-61a4-4a7b-927f-5e671f885196
Beers, Stephen A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Johnson, Peter W.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c

Lim, Sean H., Beers, Stephen A., French, Ruth R., Johnson, Peter W., Glennie, Martin J. and Cragg, Mark S. (2010) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica, 95 (1), 135-143. (doi:10.3324/haematol.2008.001628). (PMID:19773256)

Record type: Article

Abstract

Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced. In this review, we discuss the history of anti-CD20 monoclonal antibodies, detail their likely mechanisms of action, and explore ways in which they might be enhanced and further exploited in the future. In particular, as we develop our understanding of the relative contribution of the diverse effector mechanisms for different antibodies, so we hope to clarify which reagent will be the most effective in each clinical situation.

This record has no associated files available for download.

More information

e-pub ahead of print date: 22 September 2009
Published date: 1 January 2010
Keywords: cd20, monoclonal antibodies, lymphoma, immunotherapy

Identifiers

Local EPrints ID: 153653
URI: http://eprints.soton.ac.uk/id/eprint/153653
ISSN: 0390-6078
PURE UUID: cd711606-37d6-4343-9a16-2026972a6a72
ORCID for Stephen A. Beers: ORCID iD orcid.org/0000-0002-3765-3342
ORCID for Peter W. Johnson: ORCID iD orcid.org/0000-0003-2306-4974
ORCID for Mark S. Cragg: ORCID iD orcid.org/0000-0003-2077-089X

Catalogue record

Date deposited: 20 May 2010 14:51
Last modified: 14 Mar 2024 02:45

Export record

Altmetrics

Contributors

Author: Sean H. Lim
Author: Ruth R. French
Author: Mark S. Cragg ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×